PLAVIX

Compare PLAVIX  to:
Compare
Compare

Generic Name for PLAVIX

Clopidogrel (as bisulfate) 75mg, 300mg; tabs.

Legal Classification:

Rx

Pharmacological Class for PLAVIX

Platelet aggregation inhibitor.

Manufacturer of PLAVIX

BMS/Sanofi Pharmaceuticals Partnership

Indications for PLAVIX

Reduction of atherosclerotic events in: recent MI or stroke, peripheral arterial disease; non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) or ST-segment elevation acute MI; see literature.

Adult dose for PLAVIX

75mg once daily. Non-ST-segment acute coronary syndrome (give with aspirin 75–325mg once daily): give one 300mg loading dose first. ST-segment elevation acute MI (give with aspirin, with or without thrombolytics): may start with or without a loading dose. CYP2C19 poor metabolizers: may need higher doses.

Children's dosing for PLAVIX

Not recommended.

Contraindications for PLAVIX

Active pathologic bleeding (eg, peptic ulcer, intracranial hemorrhage).

Warnings/Precautions for PLAVIX

CYP2C19 poor metabolizers: diminished effectiveness and higher cardiovascular event rates. Consider testing for CYP2C19 genotype before starting therapy; consider alternative treatment if identified as poor metabolizer. Risk of bleeding (eg, surgery, ulcers, trauma, concomitant NSAIDs). Severe hepatic or renal disease. Consider discontinuing 5 days before elective surgery. Avoid lapses in therapy; if temporarily discontinued, restart as soon as possible. Increased risk of cardiovascular events if discontinued prematurely. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for PLAVIX

Avoid concomitant CYP2C19 inhibitors (eg, omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine, ticlopidine). Caution with drugs that increase risk of bleeding (eg, NSAIDs, warfarin), and with drugs metabolized by CYP2C9 (eg, phenytoin, tolbutamide, tamoxifen, warfarin, torsemide, fluvastatin, many NSAIDs).

Adverse Reactions for PLAVIX

Bleeding, GI upset/ulcers, bruising, rash, pruritus, dizziness, headache; rare: thrombotic thrombocytopenic purpura, neutropenia, agranulocytosis.

How is PLAVIX supplied?

Tabs 75mg—30, 90, 100, 500
300mg—30, 100

Related Disease:

Acute coronary syndrome
Coagulation disorders

Related Resources

FDA warns of medication errors with nimodipine oral capsules

August 02, 2010

The FDA is reminding healthcare professionals that oral nimodipine capsules should be given only by mouth or through a nasogastric tube and should never be given by intravenous administration.

Generic Lovenox approved for anticoagulation

July 26, 2010

The FDA has granted Sandoz approval of a generic version of Lovenox (enoxaparin sodium injection, from sanofi aventis).

Coumadin 1mg tablet blister packs recalled

July 14, 2010

Bristol-Myers Squibb announced a voluntary recall of several lots of Coumadin (warfarin sodium) 1mg tablet blister packs.

Sagent Pharmaceuticals' heparin sodium injection approved

July 01, 2010

The FDA has approved nine presentations of heparin sodium injection from Sagent Pharmaceuticals.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions